About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Beacon Biosignals Reports Novel Sleep EEG Results from Multiple Industry Collaborations at the American Epilepsy Society Annual Meeting

By: via GlobeNewswire

BOSTON, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Beacon Biosignals, the global leader in at-home EEG and AI-powered brain health analytics, presented two scientific posters at the American Epilepsy Society (AES) Annual Meeting. These posters highlight groundbreaking work resulting from collaborations with both Longboard Pharmaceuticals and UCB, focusing on advancing understanding of sleep disturbances in individuals with Lennox-Gastaut Syndrome (LGS) and their caregivers.

Innovative Research in LGS Caregiver Sleep Patterns

The first work, created in partnership with Longboard Pharmaceuticals, presents preliminary findings from the Dreem LGS Caregiver Study. This study leverages Beacon's FDA-cleared Dreem 3S™ EEG headband to explore sleep disturbances in caregivers of children with LGS. The results demonstrate that caregivers successfully utilized the at-home EEG device over multi-night recordings, capturing high-quality data without technologist intervention. Findings revealed significant sleep fragmentation among caregivers, likely due to the demands of nocturnal care. The study found a significant increase in Wake After Sleep Onset (WASO) in LGS caregivers of 37.79 minutes vs. 24.70 minutes in controls (p<.05), as well as shortened Sleep Onset Latency of 14.62 minutes vs. 23.43 minutes in controls. These insights provide an essential foundation for understanding the intersection of caregiver burden, stress, and sleep quality in this underserved population.

New Insights into Sleep Architecture in LGS

The second poster, developed in collaboration with UCB, focuses on the HEADFIRST study, which evaluates sleep architecture in children with LGS compared to neurotypical siblings. Using the Dreem 3S EEG headband*, this study identified marked disturbances in sleep patterns among LGS participants, including increased wakefulness during sleep periods (WASO) and fewer sleep cycles (mean of 4.6 in LGS participants vs. 2.6 cycles in neurotypical controls, p<0.05). Critically, LGS participants also exhibited a significant reduction in REM sleep (56.77 minutes, vs. 104.34 minutes in controls, p<0.05), a finding consistent with the neurological underpinnings of the syndrome.

HEADFIRST is a basket study that aims to assess the Dreem 3S headband's usability in tracking sleep and brain activity in both pediatric patients with neurodevelopmental disorders and in neurotypical controls, enrolling up to 300 participants across multiple disorders. The first phase of the study, in partnership with the Lennox-Gastaut Syndrome (LGS) Foundation, focuses on usability, reliability, and clinical utility of using Dreem for a pediatric cohort with LGS. These are the first results from the HEADFIRST study after only starting in mid-September 2024, and these findings underscore the importance of longitudinal sleep data in understanding LGS-related sleep pathology and its implications for treatment.

"Our AES presentations this year demonstrate the transformative potential of Beacon's technology in advancing neurodiagnostics," said David Matthews, PhD, Chief Business Officer of Beacon Biosignals. "By collaborating with industry leaders like UCB and Longboard, we are uncovering critical insights into epilepsy-related sleep disorders, supporting the development of novel therapies, and ultimately improving outcomes for patients and their families."

Feasibility of At-Home EEG in Clinical Trials

Beacon will take the results from these two studies forward to assess the extent to which the Dreem 3S overcomes the challenges posed by traditional wired EEG systems, which can be intrusive and disruptive for patients and their caregivers while limiting longitudinal data collection. The Dreem 3S headband, equipped with six dry-EEG electrodes and an accelerometer for head movement and body position monitoring, collects clinical-grade EEG data in the comfort of the patient's home. The device's AI-driven sleep staging capabilities have already been validated to perform equivalent to or better than human experts. The FDA's recent authorization of Beacon's Dreem 3S as the first wearable with a Predetermined Change Control Plan (PCCP) ensures the ongoing enhancement of these capabilities and reinforces Beacon's leadership in clinical-grade EEG acquisition, analytics, and sleep research.

About Beacon Biosignals

Beacon Biosignals is a health technology company transforming the development of treatments for neurological, psychiatric, and sleep disorders. Leveraging advanced machine learning, wearable EEG devices, and large real-world neurophysiology datasets, Beacon accelerates insights into brain activity to improve patient outcomes. For more information, visit https://beacon.bio.

* Device is used as research use only in pediatric populations.


Media contact:
Dan Florey
Info@beacon.bio


Primary Logo

More News

View More
After Gold Blast Soars Past $4,000, BofA Eyes $5,000 in 2026
Via MarketBeat
Tickers AEM B BAC GDX GDXJ GLD
Buyback Boom: 3 Companies Betting Big on Themselves
Via MarketBeat
Tickers AZO ESTC LMT
Analysts Flock to Upgrade DELL After Big AI-Server Guidance Boost
Via MarketBeat
Topics Artificial Intelligence
Tickers DELL MSFT
Amazon Is on the Cusp of Becoming a Grocery Disruptor
Via MarketBeat
Tickers ACI AMZN COST KR WMT
Pure Storage Hits New High: AI’s Under-the-Radar Powerhouse
Via MarketBeat
Topics Artificial Intelligence
Tickers CRWD IT MSFT PSTG
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.